FHTX vs GDTC

Foghorn Therapeutics Inc. vs CytoMed Therapeutics Limited — Valuation Comparison 2026

FHTX

Pharmaceutical Preparations
Foghorn Therapeutics Inc.
Quality
6.3
out of 10
Value Trap
24
SAFE
Price
$4.28
Last close
Models
7/13
Active
VS

GDTC

Pharmaceutical Preparations
CytoMed Therapeutics Limited
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$1.17
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType FHTX Fair ValueFHTX Upside GDTC Fair ValueGDTC Upside
Bayesian DCF Intrinsic $1.29 -69.8% $0.35 -70.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.37 -68.0%
PWERM Option-Based $8.04 +87.9% $1.27 +8.5%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for FHTX vs GDTC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FHTX vs GDTC — Which Stock Is More Undervalued?

FHTX scores higher with a 6.3/10 quality rating vs GDTC's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Foghorn Therapeutics Inc. (FHTX) and CytoMed Therapeutics Limited (GDTC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FHTX currently trades at $4.28 with a QOC of 6.3/10, while GDTC trades at $1.17 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).